Becton, Dickinson and Company Other income, net (Note 6) increased by 960.0% to $86.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 338.9%, from -$36.00M to $86.00M. Over 4 years (FY 2021 to FY 2025), Other income, net (Note 6) shows a downward trend with a 5.6% CAGR.
An increase suggests positive non-operating gains, while a decrease indicates non-operating losses or higher interest expenses.
This represents the net impact of financial activities not related to the company's core medical device operations. It i...
Varies widely based on corporate treasury and debt management strategies across the medical device sector.
other_other_nonoperating_income_expense| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.00M | -$121.00M | $4.00M | -$27.00M | -$21.00M | -$72.00M | -$8.00M | $8.00M | $17.00M | -$64.00M | -$4.00M | -$2.00M | -$13.00M | -$9.00M | -$16.00M | -$36.00M | -$33.00M | -$37.00M | -$10.00M | $86.00M |
| QoQ Change | — | <-999% | +103.3% | -775.0% | +22.2% | -242.9% | +88.9% | +200.0% | +112.5% | -476.5% | +93.8% | +50.0% | -550.0% | +30.8% | -77.8% | -125.0% | +8.3% | -12.1% | +73.0% | +960.0% |
| YoY Change | — | — | — | — | <-999% | +40.5% | -300.0% | +129.6% | +181.0% | +11.1% | +50.0% | -125.0% | -176.5% | +85.9% | -300.0% | <-999% | -153.8% | -311.1% | +37.5% | +338.9% |